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Abstract
Background: An estimated 1 in 3 American adults will have diabetes by the year 2050. Nationally, South Carolina
ranks 10
th in cases of diagnosed diabetes compared to other states. In adults, type 2 diabetes (T2DM) accounts for
approximately 90-95% of all diagnosed cases of diabetes. Clinically, provider and health system factors account for
< 10% of the variance in major diabetes outcomes including hemoglobin A1c (HbA1c), lipid control, and resource
use. Use of telemonitoring systems offer new opportunities to support patients with T2DM while waiting to be
seen by their health care providers at actual office visits. A variety of interventions testing the efficacy of
telemedicine interventions have been conducted, but the outcomes have yielded equivocal results, emphasizing
the shortage of controlled, randomized trials in this area. This study provides a unique opportunity to address this
gap in the literature by optimizing two strategies that have been shown to improve glycemic control, while
simultaneously implementing clinical outcomes measures, using a sufficient sample size, and offering health care
delivery to rural, underserved and low income communities with T2DM who are seen at Federally Qualified Health
Centers (FQHCs) in coastal South Carolina.
Methods: We describe a four-year prospective, randomized clinical trial, which will test the effectiveness of
technology-assisted case management in low income rural adults with T2DM. Two-hundred (200) male and female
participants, 18 years of age or older and with an HbA1c ≥ 8%, will be randomized into one of two groups: (1) an
intervention arm employing the innovative FORA system coupled with nurse case management or (2) a usual care
group. Participants will be followed for 6-months to ascertain the effect of the interventions on glycemic control.
Our primary hypothesis is that among indigent, rural adult patients with T2DM treated in FQHC’s, participants
randomized to the technology-assisted case management intervention will have significantly greater reduction in
HbA1c at 6 months of follow-up compared to usual care.
Discussion: Results from this study will provide important insight into the effectiveness of technology-assisted case
management intervention (TACM) for optimizing diabetes care in indigent, rural adult patients with T2DM treated
in FQHC’s.
Trial Registration: National Institutes of Health Clinical Trials Registry (http://ClinicalTrials.gov identifier#
NCT01373489
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According to the Centers for Disease Control and Preven-
tion, as many as 1 in 3 United States adults will have dia-
betes by 2050 [1]. As of 2007, approximately 23.6 million
Americans or 7.8% of the population have diabetes; nearly
6 million of which have not been diagnosed [2]. In 2007,
1.6 million new cases of diabetes were diagnosed in indivi-
duals 20 years of age and older [2]. Currently, 10.7% of all
people in this age group have diabetes [2]. In adults, type 2
diabetes accounts for about 90-95% of all diagnosed cases
of diabetes [2].
South Carolina ranks 10
th in cases of diagnosed diabetes
compared to other states [3]. The prevalence of diabetes
in SC is presently 9.6%, with an estimated 300,000-350,000
people in SC living with diabetes. As observed nationally,
more women and non-white individuals residing in SC are
affected by diabetes [3]. Nearly 1089 deaths are attributed
to diabetes, and 100,000-160,000 individuals are thought
to be undiagnosed and affected by diabetes [3].
Diabetes is the leading cause of cardiovascular disease,
strokes, blindness, and lower limb amputations and was
the seventh leading cause of death listed on United States
death certificates in 2006 [4] and in the 2009 Burden of
Disease Report in South Carolina [3]. Diabetes is asso-
ciated with significant morbidity, mortality, increased
health care utilization, and increased health care costs [4].
The estimated economic cost of diabetes in the United
States in 2007 was $174 billion with $116 billion spent
directly in medical costs, and $58 billion used for indirect
costs including lost workdays, disability, and premature
mortality [2]. People diagnosed with diabetes have average
medical expenditures that are approximately 2.3 times
higher than what expenditures are for those not diagnosed
with diabetes [2]. Additionally, the risk for death among
people with diabetes is about twice that of people without
diabetes of similar age [2].
Use of telephone contact, video-conferencing, personal
digital assistants and web-based systems offer new oppor-
tunities to bridge the gap in support for patients with dia-
betes, between face to face visits with their health care
providers; however, systematic reviews evaluating the effi-
cacy of telemedicine interventions on patient outcomes
have yielded equivocal results [5-7]. A consistent finding
across all these reviews is that there is a shortage of con-
trolled, randomized trials that implement clinical outcome
measures using sample sizes with sufficient power. How-
ever, the nature of the interventions compared (telemoni-
toring, physician decision-making support, increased
patient access to providers, electronic reminders, educa-
tional materials, or some combination of the above) and
the baseline features of the populations studied have varied
considerably, making specific conclusions difficult to draw.
While the optimal formula for technology-enhanced
patient support is far from determined, there is a growing
body of evidence to suggest that telemonitoring strate-
gies, overall, are an effective intervention for improving
metabolic control. Several small scale [8,9] and non-ran-
domized [10,11] studies have found that patients exposed
to telemonitoring interventions had lower Hemoglobin
A1c (HbA1c) values than those without. Moreover, larger
randomized controlled studies have also shown promis-
ing results. Two studies with Veteran populations
demonstrated that home telemonitoring in conjunction
with active care management resulted in lower HbA1c
values at follow up when compared to standard care
[12,13]. An open label study using ACCU-CHEK insulin
guidance software also found that HbA1c values were
significantly reduced in the experimental group and suc-
cessfully maintained at one year follow-up [14]. In addi-
tion, adoption of a mobile (wireless) telemonitoring
device with a diverse inner-city population was recently
f o u n dt or e s u l ti ns i g n i f i c a n t l yr e d u c e db l o o dp r e s s u r e
and decreased blood sugar when compared to usual care
[15].
But perhaps the most comprehensive randomized com-
parison of telemonitoring interventions yet completed is
the IDEATel study with 1665 Medicare recipients [16].
Telemedicine case management was assessed in middle-
aged Medicare recipients with diabetes living in federally
designated medically underserved areas of New York
State. Participants were randomized to one of two groups:
usual care or intervention group. Those randomized to the
intervention group received a home telemedicine unit cap-
able of (1) videoconferencing with a nurse case manager,
(2) remote monitoring of glucose and blood pressure with
electronic upload and integration into the electronic medi-
cal records at the participating hospital, (3) dial-up Inter-
net service allowing the patients to access their own
clinical data and leave messages for the nurse case man-
ager, and (4) access to an educational Website created by
the American Diabetes Association (ADA). At 1 year, the
mean HbA1c was significantly lower in participants in the
intervention group, having improved from 7.35% to 6.97%.
For those with a baseline HbA1c of 7 or greater, the
HbA1c improved from 8.35% to 7.42%. Adjusted net
reductions also favored the intervention group: HbA1c,
0.18% (p = 0.006), systolic and diastolic blood pressure, 3.4
mm Hg (p = 0.001) and 1.9 mm Hg (p < 0.001), and low
density lipoprotein (LDL) cholesterol, 9.5 mg/dL (p <
0.001). Patients were also blindly assessed annually over a
period of five years. It was found that the telemedicine
group scored better than the standard care group on vir-
tually all outcome measures at each annual evaluation.
In a smaller RCT of 30 patients with type 2 diabetes in
Maryland [9], the feasibility of a cell phone-based diabetes
software system in conjunction with an interactive web-
based information management system were assessed.
Compared to the control patients, those in the intervention
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(0.68% in the controls; p < 0.02, one tailed). In addition to
improving diabetes outcome measures, 84% of those in the
intervention group were able to facilitate optimal treatment
decisions and have their medications changed or titrated
(23%, p = 0.002).
Nurse case management has, in general, been shown to
h a v eap o s i t i v ei m p a c to nt r e atment adherence, clinical
outcomes and quality of life measures in chronic disease
[17]. Evidence for the efficacy in the area of diabetes con-
trol is considerable. Several randomized controlled trials
have shown that nurse case management can be an effec-
tive strategy for the reduction of HbA1c values in patients
with diabetes [16,18-20]. Indeed, a recent meta-analysis of
29 studies found that nurse case management was a useful
clinical strategy for the reduction of HbA1c values in
patients with poorly controlled diabetes [21]. A recent
study using a retrospective cohort design revealed that the
use of nurse case management improved glycemic control
with or without medication adjustment [22]. Even in stu-
dies in which HbA1c is not directly impacted, measures
such as BP and emotional distress [23], and emergency
department utilization [24] have improved.
The FORA system is an inexpensive, off-the-shelf,
state-of-the-art technology whereby a person/caregiver
and a provider can communicate accurately on data
needed for self-management of diabetes [25]. The system
is comprised of a 2-in-1 Blood Glucose and Blood Pres-
sure monitor (Figures 1 & 2) which can provide an easy-
to-use operation for users to accomplish two important
tests. The measured results can be uploaded to a PC or
web-based software by using a RS232 cable via a commu-
nication device to connect FORA glucose monitor and
web-based FORA Telehealth System using a phone
modem (Figure 3). The provider receives the readings,
which are stored with previous readings for the patient.
The provider can review the patient records on a secure
website at any time. In addition, a nurse case manager
can review the glucose and blood pressure readings daily
and titrate medications as needed under the supervision
of the patients’ primary care provider. The widespread
availability of analog phone lines presents an opportunity
to employ a technology that uses a modem to transmit
information via analog phone lines, to enhance patient-
provider communication and adherence to treatment.
This paper describes the rationale, study aims and objec-
tives, and research design and methods of an ongoing
four-year, randomized clinical trial testing the effectiveness
of technology-assisted case management intervention
(TACM) using the FORA 2-in-1 and Telehealth System
for diabetes in Federally Qualified Community Health
Centers (FQHCs). The long-term goal of the project is to
achieve improvement in diabetes-related outcomes in this
patient population.
Rationale
Numerous barriers to effective health care delivery in
rural, underserved and minority communities have been
identified. These include limited access to care, inability
to afford medications, poor health literacy, and physi-
cian/provider mistrust. Conversely, studies have clearly
shown that increased frequency of blood glucose testing,
adherence to medications and more frequent provider
visits dramatically improve glycemic control and out-
comes in patients with diabetes. Sophisticated informa-
tion technology, such as the FORA system, offers the
potential to address several oft h eb a r r i e r sto effective
care by providing: (1) Reinforcement and positive feed-
back to patients that should increase adherence; (2) Real
time access to blood glucose and blood pressure data for
providers that should lead to more rapid optimization of
treatment plans; and (3) Alerts to patients and providers
if certain parameters are exceeded, e.g. sustained blood
g l u c o s el e v e l sa b o v eap r e - e s t ablished threshold, trigger-
ing more rapid interventions. However to be successful,
the technology needs to be implemented as part of an
integrated diabetes management plan that is workable
within a community health care setting. One can envision
three levels of diabetes care, escalating in intensity: Usual
Care: (Low Intensity) Typical office-based practice. In
this setting the patient is custodian of his/her own care.
Between scheduled visits, the patient is responsible for
complying with prescribed treatment including medica-
tions, diet and exercise regimen, blood glucose monitor-
i n g ,a n df o l l o wu pv i s i t s .C o n t a c tb e t w e e ns c h e d u l e d
visits is patient-initiated and occurs when the patient per-
ceives a problem with the treatment plan. For patients
with poorly controlled T2DM, which is often asympto-
matic prior to the onset of serious complications, this is a
particularly ineffective strategy. Case Management:
(Intermediate Intensity). In this model, a clinic-based
nurse case manager assumes some responsibility for
patient compliance and chaperones them through the
health care system. The intensity of the intervention may
vary, but would typically include regular telephone con-
tact with the patient between visits to reinforce compli-
ance, provide reminders about scheduled appointments
a n di n q u i r ea b o u tg l y c e m i cc ontrol. The case manager
notifies the physician when problems are identified. If the
case manager is a qualified medical professional (e.g. a
registered nurse or certified diabetes educator), then
medication/dose changes may be implemented based on
the phone contact according to a physician-approved
protocol. The case management approach has previously
been shown to be moderately effective in increasing
patient adherence. In dealing with T2DM, the shortcom-
ings are that contact is limited to prescheduled calls, the
accuracy of data is limited by patient recall or recitation
of blood glucose readings over the phone, and excepting
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ing authority, changes require direct physician input and
are implemented between scheduled visits only in cases
where control is poor. Technology-Assisted Case Man-
agement (TACM): (High Intensity). This model capita-
lizes on information technology like the FORA system to
link a case manager to poorly controlled diabetics in real
time. Clearly a model that is applicable only to patients
in need of intensive intervention, the advantages includes
accurate data transfer to a medical decision maker and
positive reinforcement/feedback to the patient via the
FORA system to enhance adherence. If the case manager
has physician-supervised prescriptive authority, then
medication adjustments can be made daily or weekly, if
needed, to achieve and maintain control. More frequent
interventions, combined with improved compliance with
medications and testing frequency, the strategies that are
known to work, are enabled by this approach.
The study will use technology-assisted case manage-
ment to target low income patients served in Federally
Qualified Health Care Centers with poorly controlled
T2DM residing in coastal South Carolina. Due to lack
of access to care and low socioeconomic status, this
population is at the highest risk for complications aris-
ing from uncontrolled T2DM.
Study Aims & Objectives
The primary objective of this study is to test the effective-
ness of technology-assisted case management intervention
using the FORA 2-in-1 and Telehealth System for diabetes
in improving HbA1c levels in indigent, rural adult patients
with type 2 diabetes treated in Federally Qualified Com-
munity Health Centers. The primary outcome will be
HbA1c at 6 months post-randomization, while the sec-
ondary outcomes will be blood pressure control and qual-
ity of life at 6 months post-randomization.
Methods
The study is a 2 group randomized controlled trial with
randomization of individual participants, blinded out-
comes assessments at baseline, 3-months, and 6-months,
and concurrent economic evaluation.
Location and Setting
This study will be conducted primarily in eight commu-
nity-based adult medicine primary care practices within
the Franklin C. Fetter Family Health Center, Inc. Addi-
tional practices will be added if adequate sample is not
obtained from the primary target practices. The Franklin
C. Fetter Family Health Center, Inc. is a FQHC with eight
adult medicine primary care clinics, 1 pediatric primary
Figure 1 The FORA Telehealth System.
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locations. The clinics provide service to residents in Berke-
ley, Charleston, and Dorchester Counties of South Caro-
lina. Demographic characteristics of the clinic population
are as follows: 70% African American, 25% White, 5% His-
panic/other, 70% with income below 100% of federal pov-
erty level, and 46% uninsured. The structure of each site is
similar with the same number of practitioners and staff.
Ethics and Trial Registration
The study is funded by grant W81XWH-10-2-0057 from
the United States Department of Defense. The trial is
approved by the Institutional Review Board (IRB) of the
Medical University of South Carolina (Pro00009204).
The trial is registered on the United States National
Institutes of Health Clinical Trials Registry (http://Clini-
calTrials.gov identifier# NCT01373489), available online
at: http://clinicaltrials.gov/ct2/show/NCT01373489
Trial Population and Recruitment
A total of 200 participants with T2DM will be rando-
mized to one of two groups: 1) technology-assisted nurse
case management or 2) usual care. We will use two com-
plementary approaches to identify eligible study subjects.
The first method will consist of systematic identification
of patients with T2DM. We have obtained IRB approval
for a partial waiver of HIPAA and will use clinic-billing
records over the previous 12-month period to identify
individuals with ICD-9 codes consistent with a diagnosis
of type 2 diabetes. The physicians of eligible patients will
be notified of their patients’ potential eligibility and asked
permission to enroll their patients in this study. After
consent is obtained from the physicians, letters of invita-
tion on clinic letterhead signed by the patient’s physician
will be mailed to patients from the study clinics. The let-
ter will provide information about the study, explain the
study requirements, and clarify that only individuals who
meet certain criteria will be eligible to participate in the
study. The letter will include an addressed and stamped
post-card that individuals can mail back to indicate inter-
est or lack of interest in participating in the study. In
addition, the letter will provide a telephone number that
interested individuals can call to receive detailed infor-
mation about the study. In the letter, individuals will also
Figure 2 The FOR A 2-in-1 Blood Glucose and Blood Pressure Machine (FORA D15g).
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weeks unless they mail back the post card or call to
decline being contacted. Individuals who mail back the
post card and express interest or call the provided tele-
phone number will receive detailed information about
the study. Individuals who agree to participate will be
asked to provide written consent and will be scheduled
for the initial screening assessment.
The second method will consist of referrals from physi-
cians, other clinic staff such as nurses, or patients them-
selves in response to recruitment flyers for the study. The
Principal Investigator will share the goals of the study and
inclusion/exclusion criteria with physicians and clinic staff
during clinic administrative meetings. Physicians and clinic
staff will be asked to refer appropriate individuals to the
study research assistants. In addition, IRB approved
recruitment flyers will be posted in prominent locations in
the study clinics.
Regardless of recruitment pathway, research staff mem-
bers will obtain written informed consent, complete
screening for eligibility, and assure that participants meet
criteria for inclusion and participation in the study. The
procedure and risks are explained to the patient and the
consent form signed as per standard clinical practice.
Individuals who meet eligibility criteria then complete
the remainder of the assessment battery (see Tables 1).
Randomization
All participants are randomly assigned to one of the two
study arms (n = 100 per arm). The study coordinator will
verify all eligibility criteria prior to randomization. The
procedure and risks will be explained to the participants
and the consent form signed as per standard clinical
practice. All participants are randomly assigned to either
t h ei n t e r v e n t i o n( T A C M )( n=1 0 0 )o ru s u a lc a r e( U C )
(n = 100) groups. Randomization takes place in waves,
with approximately 50 subjects randomized every 6
months. The randomization sequence is generated by the
research team biostatistician using a permuted block ran-
domization scheme stratified by clinic site. The rando-
mized assignment for eligible participants is accessible to
the study coordinator using an envelope-based system at
each clinic site. Once a randomization assignment is pro-
vided, the participant is entered into the study and will
Figure 3 Operation Instructions for the FORA Telephone/Ethernet Gateway.
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dance with the CONSORT guidelines [26].
Intervention and Control Groups
There is one active treatment group (technology-assisted
case management) and a usual care group.
Overview of the Technology-assisted Case Management
(TACM) Intervention
The TACM intervention uses the FORA 2-in-1 Telehealth
System for diabetes to link a case manager to poorly con-
trolled patients with diabetes in real time. Participants will
be assigned the FORA 2-in-1 Telehealth System and pro-
vided glucose test strips to allow testing at least once a
day. They will be asked to perform glucose testing and
blood pressure measurement using the FORA system once
daily. They will be asked to upload the measurements daily
as soon as possible after the test is performed. The nurse
case manager will have access to a secure server to which
the uploaded measurements are stored in real time. Under
the supervision of the patient’s primary care provider, the
nurse case manager will make medication adjustments
weekly based on the uploaded readings and an evidence-
based treatment algorithm approved by the primary care
provider. The TACM intervention in essence facilitates
increased frequency of self-monitoring and titration of
medications in response to test values to optimize diabetes
and blood pressure control. Details of the TACM inter-
vention are provided below.
Algorithms for Glucose and Blood Pressure Control
We developed two separate algorithms for control of
hyperglycemia and high blood pressure based on American
Diabetes Association and American Association of Clinical
Endocrinologists guidelines in collaboration with physi-
cians at the study clinics. The algorithms went through an
iterative process to ensure that evidence was tailored to the
unique needs of FQHCs. For e x a m p l ew ec h o s eg e n e r i c
versions and low cost alternatives when possible. We also
tried to use medications that were on formulary at the
respective study clinics. The nurse case manager will be
trained to follow the approved algorithms, but the ultimate
decision for medication titration will rest with the treating
physician.
Glycemic and Blood Pressure Control Targets
The following indices will be used to determine whether
participants are meeting treatment goals. These goals
conform to current standard of care in outpatient dia-
betes management.
￿ Fasting/pre-prandial Blood Glucose: < 110
mg/dl (range 70-109 mg/dl)
Table 1 Data Collection Schedule
Questionnaires/Measurements Baseline
Visit
3-month
visit
6-month
visit
Primary Outcome Measure
Hemoglobin A1c X X X
Secondary Outcome Measures
Blood Pressure X X X
Quality of life (SF-12) X X X
Process Measures
Diabetes Knowledge Questionnaire X X X
Diabetes Fatalism Scale X X X
Perceived Diabetes Self Efficacy Scale X X X
Summary of Diabetes Self-Care Activities Scale X X X
Morisky Medication Adherence Scale X X X
Self-Report Measures
Patient Demographics X
Social support X
Health Literacy X
Depression (PHQ-9) X
Medical Comorbidity (Charlson Index) X
Service Delivery Perceptions/Treatment Credibility X
Resource Use X X X
Egede et al. Trials 2011, 12:231
http://www.trialsjournal.com/content/12/1/231
Page 7 of 12￿ Bedtime Blood Glucose: < 130
mg/dl (range 70-129 mg/dl)
￿ Two-hour post-prandial Blood Glucose: < 140
mg/dl (range 110-139 mg/dl)
￿ HgbA1C target: <
7.0%
￿ Blood pressure <
130/80 mmHg
Role of the Case Manager
The case manager is to serve as an adjunct to usual care
by providing more frequent contact between the patient
and his/her health care provider. This will be accom-
plished through: (1) Real time tracking of patient-gener-
ated blood glucose and blood pressure data using the
FORA 2-in-1 and Telehealth System for diabetes; (2)
Minimum of monthly phone calls to participants to rein-
force diabetes self-management behaviors, e.g. medica-
tion compliance, blood glucose monitoring, diet/exercise
programs; (3) More frequent phone calls as needed for
patients undergoing active changes in management; (4)
Telephone reminders about upcoming scheduled
appointments; and (5) Use of uploaded blood glucose
and blood pressure data and information obtained from
participant contact to determine need for additional
interventions. The case manager will function as liaison
between the primary provider and the participant, identi-
fying those participants in need of additional intervention
and facilitating implementation of a revised treatment
plan.
Case Manager Telephone Follow-up
The nurse case manager will be responsible for conducting
regular follow-up by telephone with all TACM interven-
tion participants. The initial phone follow-up will occur
within two weeks of the initial study visit. Thereafter, the
minimum frequency of phone follow-up will be monthly
for participants who are meeting treatment targets based
upon weekly review of uploaded data. More frequent con-
tact is permitted for participants not meeting treatment
targets and in whom active interventions are ongoing.
Routine follow-up calls will review the following: (1) Inter-
val health-related events and changes in medications; (2)
Current level of glycemic and blood pressure control,
based on data logged in the FORA system; (3) Frequency
and severity of hypoglycemia on the current therapy based
on both FORA system data and patient perception of
hypoglycemia; (4) Reinforce adherence with diet/exercise
program and medications; (5) Reinforce participant educa-
tion relating to caring for diabetes, treatment of hyper/
hypoglycemia and safe driving rules; (6) Remind partici-
pants about upcoming scheduled appointments with their
primary provider and/or study visits; and (7) Answer parti-
cipants’ questions.
Usual Care Group
Apart from study visits, participants will be followed by
their Franklin C. Fetter PCPs. The provider will be respon-
sible for determining treatment parameters, making
changes in the treatment regimen, and determining the
timing of follow up visits. Between scheduled office
encounters, contact between participant and provider will
be patient initiated. The provider may use clinic nurses to
follow up on problematic patients or patients with abnor-
mal results. In essence, this group will receive the current
standard of care at the study clinics.
Study Instruments and Data Collection Schedule
See Figure 4 and Tables 1 and 2, for the study design
and study flow, data collection schedule, and data col-
lection measures and instruments, respectively.
Intervention Delivery, Treatment Integrity, and Treatment
Adherence
A full-time registered nurse (RN) will conduct the screen-
ing, patient scheduling, consent, and enrollment proce-
dures as well as deliver the case management intervention.
A blinded research assistant (RA) will conduct all study
assessments. A data coordinator will enter all study related
data into a secure web-based data system and perform all
related data tracking and coordination duties.
Training and Supervision of Interventionist (Nurse Case
Manager)
Training in the basic elements of the treatment algorithms
and ongoing supervision and oversight of the case man-
ager will be provided by the study physicians (a board cer-
tified endocrinologist and a board certified internist).
Training will consist of two full days of didactic training
on diabetes and hypertension in year 01 and then one day
booster sessions in years 2-5 to maintain knowledge. In
addition, the case manager will receive two full days of
training on the FORA system and use of the secure web-
site in Yr 01 and a full day of booster training in subse-
quent years. The nurse case manager will also participate
in weekly research meetings to discuss challenging
patients and resolve conflicts. The study physicians will be
available by telephone at all other times to support the
n u r s ec a s em a n a g e r .
Treatment fidelity checks
In order to ensure that treatments are competently admi-
nistered in accordance with the study protocol, a 20%
random sample of intervention study charts will be
reviewed along with the uploads from the secure site for
the corresponding patients to ensure the case manager is
adhering to the treatment algorithms. To evaluate adher-
ence, rating forms will be developed based upon the
treatment protocol to determine if the nurse case man-
ager escalated treatment as appropriate and how well she
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The study physicians will review and rate the randomly
selected patient charts to assess for fidelity to treatment.
Patient adherence to treatment protocol
This is a very important aspect of this study given the
intensity of the intervention protocol. We will adopt the
following strategies to ensure an optimal level of com-
pliance: (1) At enrollment, we will stress the importance
of daily testing with the FORA system and daily upload
of data; (2) We will place reminder telephone calls to
participants on a weekly basis to remind them to test
and upload data; (3) As described earlier, we will request
the names and telephone numbers of three of the parti-
cipant’s friends and/or relatives who know how to reach
the participant in the event we are unable to reach him
or her; (4) The research staff will be flexible in accom-
modating participants’ schedules and every attempt will
be made to schedule research visits to coincide with
clinic appointments. In addition, we will reimburse the
participants ($25 each) for baseline, 3-, and 6-month fol-
low-up visits.
Treatment enactment
The behaviors that are the target of this intervention are
daily testing and uploading of blood glucose and blood
pressure results from the FORA system. We will assess
adherence to these behaviors based on review of fre-
quency of uploads to the secure server.
Primary Outcome Measure
The primary outcome is HbA1c level at 6 months of fol-
low-up.
Sample Size Determination and Power Analysis
For the continuous longitudinal clinical and quality of
life outcomes for Primary Aims 1 and 2 (e.g., trajectory
of HbA1C, BP, and SF-12 total scores), with 80 partici-
pants randomized 1:1 to each intervention group
(TACM or UC), we will have 85% power to detect at
least a 0.4 standardized (sd units) effect size between
the TACM vs. UC intervention groups [assuming 3 time
points (baseline, 3 and 6 months); intra-class correlation
no greater than 0.6; level of significance (a) = 0.05, two-
tailed ]. To account for dilution effect of ITT analyses
and “administrative” dropout, i.e., those who drop out
immediately upon randomization (do not receive a treat-
ment or return for a post baseline visit), we inflated the
sample size by 20% to achieve a final ITT sample size of
100 subjects randomized to each intervention group (N
= 200).
Data Analysis
Preliminary Descriptive Analyses
Baseline values for demographic, clinical, and other
putative prognostic variables will be compared for
imbalance across the two treatment conditions (TACM;
UC). These analyses will identify potential confounding
variables to be used as covariates in subsequent analyses
and will include race/ethnicity, gender, age, social sup-
port, health literacy, concurrent medical illness, depres-
sion, motivation etc. To investigate potential limits on
generalizability, we will compare characteristics of the
premature exits/protocol non-adherent with those who
were completers/protocol adherent. Characteristics of
participants who do not complete the study or do not
 
Baseline Assessment 
Randomization 
Technology-
assisted Case 
Management 
Intervention 
Group 
Usual Care 
Group 
6 Month Follow-up 
Screening and Eligibility 
Assessment 
3 Month Follow-up 
Figure 4 Description of Study Design and Study Flow.
Egede et al. Trials 2011, 12:231
http://www.trialsjournal.com/content/12/1/231
Page 9 of 12comply with the treatment will be compared for both
conditions.
Statistical Analysis Plan
The longitudinal trajectory of primary and secondary clini-
cal (HbA1C, blood pressure) and quality of life outcomes
will be compared using the generalized linear mixed mod-
els (GLMM) approach. In addition to accommodating a
wide range of distributional assumptions [dichotomous/
categorical (e.g., binomial), continuous (e.g., normal), ordi-
nal, count (e.g., Poisson)], the approach accommodates
missing data, time varying or invariant covariates, and
multilevel data (clustering) such as repeated measure-
ments on participants and possible cluster effects within
clinics through inclusion of random effects in the model
[27]. For the continuous outcomes such as blood pressure
and HbA1C, GLMM is equivalent to a linear mixed effect
model (MEM) approach. MEM analyses estimate indivi-
dual change in outcome for each participant in addition to
estimating average change in outcome within each inter-
vention arm. Covariables, such as age, race, gender, medi-
cal comorbidity, social support, health literacy, and
depression severity, will be added to the MEM model to
adjust for putative confounding variables. For the dichoto-
mous outcome, proportion (%) of participants who drop-
out prior to the 6-months end-of-study time point, we will
compare proportion dropout for the TACM vs. UC inter-
vention groups using GLMM for a binary outcome
[equivalent to logistic regression analysis for the single
end-of-study endpoint]. Appropriate contrasts will be spe-
cified to obtain individual time point comparisons of inter-
est (e.g., 3 months, 6 months). Variables will be considered
as fixed (e.g., primary intervention effect) or random (e.g.,
clinic) as appropriate.
Exploratory analyses In additional exploratory analyses,
we will examine the effect modification of baseline fac-
tors, such as race/ethnicity age, gender, social support,
health literacy, medical comorbidity) on the relationship
between clinical/quality of life outcomes and intervention
using GLMM/MEM analyses as described above. These
analyses involve the inclusion of a putative moderator
variable (e.g. race/ethnicity) by intervention interaction
term in the multivariable model. A significant interaction
effect would suggest that the effect of the putative mod-
erator on the outcome of the intervention is different
Table 2 Data Collection Measures and Instruments
Measure Data Collected Method
Primary
Outcome
Hemoglobin A1c Blood specimens will be obtained at baseline, 3-, and 6-months visits.
Secondary
Outcomes
Blood Pressure Blood pressure readings will be obtained at baseline, 3-, and 6-months visits.
Quality of life Quality of life will be measured by the SF-12 [31], which is a valid and reliable instrument to measure
functional status.
Process
Measures
Information This will be measured by the 24-item Diabetes Knowledge Questionnaire (DKQ) [32]
Motivation This will be measured with the 12-item Diabetes Fatalism Scales (DFS) [33].
Self-Efficacy This will be measured by the perceived diabetes self-management scale (PDSMS) [34].
Behavioral Skills This will be assessed with the Summary of Diabetes Self-Care Activities (SDSCA) scale [35].
Medication
Adherence
This will be measured with the new 8-item self-report Morisky Medication Adherence Scale (MMAS) [36].
Self-report
measures
Demographics Previously validated items from the 2002 National Health Interview Survey [37] will be used to capture age,
gender, race/ethnicity, marital status, household income, and health insurance.
Social support The Medical Outcomes Study (MOS) Social Support Survey [38] will be used to measure social support.
Health Literacy The abbreviated version of the Test of Functional Health Literacy in Adults (S-TOFHLA) [39] is designed to
rapidly screen patients for potential health literacy problems.
Depression The PHQ-9 is a brief questionnaire that scores each of the 9 DSM-IV criteria for depression [40].
Medical
Comorbidity
The patient’s history of medical comorbidity will be documented using a standardized and validated
questionnaire [41].
Service Delivery
Perceptions
This will be assessed with 5 items that have been previously validated in mental health studies. The items
were slightly modified to be relevant to diabetes.
Treatment
Credibility
To assess for differences in outcome expectancy, a modified treatment credibility scale developed by
Borkovec and Nau (1972) will be used [42].
Resource Utilization
& Cost
The perspective of cost will be that of the payer. Previously validated questions on resource utilization will
be administered as a part of the baseline, 3-, and 6-month visits.
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Page 10 of 12across levels of the moderator variable. For example, a
significant race × intervention interaction would suggest
that one intervention (e.g., TACM) may be more benefi-
cial for African Americans than Whites.
We will also explore the potential mediating effect of
changes in diabetes knowledge, motivation, self-efficacy,
and behavioral skills on intervention effectiveness out-
comes using the GLMM modeling approach. These ana-
lyses address the question of whether the putative
mediating variables help explain the relationship between
the effectiveness outcomes (e.g. improvement in HbA1C
or blood pressure control) and the primary independent
variable (intervention group). It is posited that variation in
intervention accounts for variation in the mediators (e.g.
changes in diabetes self-care activities) and variations in
mediators account for variations in intervention effective-
ness (improvement in HbA1C or blood pressure control).
For these analyses, we will follow the recommended meth-
ods as described by Baron & Kenney, 1986; Holmbeck,
1997; and MacKinnon et al., 2007 [28-30], and conclusions
will be carefully considered in light of the assumptions
that accompany mediation analysis.
Discussion
The study was funded in June 2010. Our Institutional
Review Board (IRB) and second level administrative review
by the Department of Defense IRB were obtained in
August 2011. Study recruitment date is anticipated to start
in October 2011, with all follow-up assessments associated
with the study expected to be completed by July 2014.
The study is inherently novel in that it optimizes two
strategies that have been shown to improve glycemic con-
trol: nurse case management and telemonitoring interven-
tions to improve effective health care delivery in rural,
underserved and minority communities with type 2 dia-
betes. The study provides a practical and sustainable sys-
tem of diabetes management that will help low income
patients achieve and maintain goals within established
treatment guidelines regardless of geographic location.
The study employs novel and innovative information tech-
nology to improve communication between patients and
providers and improve patient adherence with prescribed
therapy. It is expected that the results of this study would
enhance the efficiency of care, speed the implementation
of effective treatment plans, generate sustained improve-
ment in glycemic control, decrease the morbidity and
early mortality associated with T2DM, and ultimately gen-
erate significant reductions in overall health care costs.
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